Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
← catalyst calendarSponsored by Ocular Therapeutix, Inc. (industry) · OCUL — their whole pipeline →. With Fortrea, Duke University.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
344actual
Sites
108
Countries
Argentina, Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-29 | actual | When the study began enrolling |
| Primary completion | 2026-04-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-27 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Neovascular Age-Related Macular Degeneration
Interventions
- Drug: OTX-TKI (axitinib implant)
- Drug: Aflibercept
Primary outcome
what the primary-completion date above is the date OFBest corrected visual acuity (BCVA)
measured Up to 36 Weeks
Permalink · OCUL's whole pipeline · Catalyst calendar · Every registered study · What changed